Thymopentin vs Thymosin Alpha-1

Thymopentin is the active pentapeptide of thymopoietin; thymosin alpha-1 is a separate thymic peptide. Both were developed as immune modulators, with thymosin alpha-1 reaching wider approval.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Thymopentin

A synthetic pentapeptide matching the active site (residues 32–36) of the thymic hormone thymopoietin, studied as an immunomodulator.

BEST STUDIED FOR

Repair & immune

Read the cited profile →

🧪

	Thymopentin	Thymosin Alpha-1
The key difference	Five-amino-acid fragment of thymopoietin	28-amino-acid thymic peptide
Class	Repair & immune	Repair & immune
Mechanism	Thymopentin reproduces thymopoietin’s activity on T-cell differentiation and immune balance; it was investigated in atopic dermatitis, rheumatoid arthritis and immunodeficiency in the 1980s.	Thymosin α1 acts on innate and adaptive immunity — reported to signal through Toll-like receptors on dendritic cells and to promote T-cell maturation — which is why it is studied as an immune "modifier" in infections, vaccines and oncology.
Status	Registered in some countries historically; mostly 1980s–90s clinical research, with renewed interest in hybrid peptides.	Approved (thymalfasin) in over 30 countries, mainly for hepatitis B/C and as an immune adjuvant; not registered in South Africa. Ongoing trials in oncology.
Reported safety signals	A 1985 overview of its preclinical safety programme reported a favourable profile.	Reviews describe a favourable tolerability record in clinical use; injection-site discomfort is the most cited effect.
A key study	Describes thymopentin as the active-site pentapeptide (residues 32–36) of thymopoietin. (Surv Immunol Res 1985, PMID 2994196)	A comprehensive review of thymosin α1 in immunocompromised states, malignancy and vaccine response. (World J Virol 2020, PMID 33362999)

Thymosin alpha-1 has the broader modern dataset; thymopentin is an older immunomodulator with mixed results. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Thymopentin] Thymopoietin to thymopentin: experimental studies — Surv Immunol Res 1985. PMID 2994196
[Thymopentin] Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis — J Am Acad Dermatol 1983. PMID 6339571
[Thymopentin] Thymopentin and splenopentin as immunomodulators. Current status — Immunol Res 1998. PMID 9638477
[Thymosin Alpha-1] Thymosin alpha 1: A comprehensive review of the literature — World J Virol 2020. PMID 33362999
[Thymosin Alpha-1] Historical review of thymosin α 1 in infectious diseases — Expert Opin Biol Ther 2015. PMID 26098768
[Thymosin Alpha-1] Aging and Thymosin Alpha-1 — Int J Mol Sci 2025. PMID 41373628

FREQUENTLY ASKED

What is the difference between Thymopentin and Thymosin Alpha-1?

Thymopentin is the active pentapeptide of thymopoietin; thymosin alpha-1 is a separate thymic peptide. Both were developed as immune modulators, with thymosin alpha-1 reaching wider approval.

What is the regulatory status of Thymopentin and Thymosin Alpha-1?

Thymopentin: Registered in some countries historically; mostly 1980s–90s clinical research, with renewed interest in hybrid peptides. Thymosin Alpha-1: Approved (thymalfasin) in over 30 countries, mainly for hepatitis B/C and as an immune adjuvant; not registered in South Africa. Ongoing trials in oncology.

What safety signals have been reported?

Thymopentin: A 1985 overview of its preclinical safety programme reported a favourable profile. Thymosin Alpha-1: Reviews describe a favourable tolerability record in clinical use; injection-site discomfort is the most cited effect.

Which studies is this comparison based on?

For Thymopentin: “Thymopoietin to thymopentin: experimental studies” (PMID 2994196); “Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis” (PMID 6339571); “Thymopentin and splenopentin as immunomodulators. Current status” (PMID 9638477). For Thymosin Alpha-1: “Thymosin alpha 1: A comprehensive review of the literature” (PMID 33362999); “Historical review of thymosin α 1 in infectious diseases” (PMID 26098768); “Aging and Thymosin Alpha-1” (PMID 41373628).